Who makes Nifidipine & LipoCol?

Nifidipine & LipoCol is developed by Taipei Medical University WanFang Hospital.

What development phase is Nifidipine & LipoCol in?

Nifidipine & LipoCol is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Nifidipine & LipoCol

Taipei Medical University WanFang Hospital · FDA-approved active Small molecule Quality 0/100

Nifidipine & LipoCol, marketed by Taipei Medical University WanFang Hospital, is a combination therapy currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports its competitive position. The primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Generic name	Nifidipine & LipoCol
Sponsor	Taipei Medical University WanFang Hospital
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Effect of LipoCol Forte® Capsules on the Pharmacokinetics of Nifedipine After Administering Single-dose Combination to Healthy Subjects (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Nifidipine & LipoCol CI brief — competitive landscape report
Nifidipine & LipoCol updates RSS · CI watch RSS
Taipei Medical University WanFang Hospital portfolio CI